Philips Respironics

Philips Respironics is a United States medical-device business owned by Koninklijke Philips N.V. and headquartered in Murrysville, a Pittsburgh suburb in Pennsylvania. The business originated as Respironics, founded in 1976 by Gerald E. McGinnis. It began with anesthesia masks and other airway-management products before becoming one of the early commercial developers of equipment for obstructive sleep apnea and non-invasive respiratory support. The company’s development was closely associated with continuous positive airway pressure, or CPAP, therapy. Building on the nasal CPAP concept developed by physician Colin Sullivan, Respironics obtained U.S. Food and Drug Administration clearance for its system in 1984 and began commercial sales the following year. It later developed bi-level ventilation technology, generally marketed through the BiPAP family, which expanded the company’s relevance beyond sleep apnea to other breathing disorders, including chronic obstructive pulmonary disease and related respiratory conditions. Respironics grew through both product development and acquisitions. It acquired LIFECARE International, a ventilator manufacturer, in 1996; Healthdyne Technologies, a competitor in sleep-apnea care, in 1998; and Novametrix, a specialist in medical monitoring and sensors, in 2002. The company became publicly traded in 1988 under the ticker RESP. Philips announced an agreement to acquire Respironics in December 2007 and completed the acquisition process in March 2008. Following the transaction, Respironics became part of Philips’ healthcare activities while retaining a recognizable brand identity in respiratory and sleep-care markets. Its portfolio has included CPAP and bi-level non-invasive ventilation devices, hospital ventilators, oxygen concentrators, infant apnea monitors, asthma-treatment solutions, diagnostic equipment, masks, and other airway-management products. Its products have served hospitals, durable-medical-equipment providers, home-care organizations, clinicians, and patients receiving treatment at home. The brand has operated internationally, although product availability and regulatory status vary by market. Philips Respironics became the subject of extensive regulatory, legal, and public scrutiny after Philips announced a large recall in June 2021 involving certain sleep and respiratory devices. The affected devices used polyester-based polyurethane sound-abatement foam that could degrade under some conditions and potentially release particles and chemicals into the breathing pathway. The recall affected several widely used device families, including many DreamStation models, and extended across the United States and other countries. The episode generated patient complaints, lawsuits, regulatory investigations, replacement-device programs, and restrictions on the marketing of certain new devices in the United States. Philips has said that patient safety is its priority, expressed regret for the distress caused by the recall, and funded remediation and replacement efforts. Investigative reporting and regulatory proceedings examined the company’s handling of complaints and its communications with U.S. regulators. Subsequent testing, settlements, and compliance measures continued to shape the business. In 2024, a previously announced consumer-related settlement was reported as having increased to approximately US$1.1 billion; that figure concerns litigation and remediation and is not a measure of brand sales. Under a consent decree involving the U.S. Food and Drug Administration and the Department of Justice, Philips Respironics has faced restrictions on selling new respiratory devices in the United States. Outside the United States, the business continues to offer, subject to local authorization, sleep-apnea diagnosis and treatment equipment, oxygen-concentration products, infant monitoring, asthma solutions, and hospital respiratory-care systems.

Gerald E. McGinnis established Respironics in 1976 in the Pittsburgh area. The company’s earliest manufacturing work centered on anesthesia masks, with initial research and production reportedly taking place on a small scale before the business developed dedicated facilities. Early offerings also included endotracheal and tracheostomy products, giving the company a foundation in airway management and respiratory support. Respironics entered sleep medicine through nasal CPAP. The company commercialized a CPAP system based on the nasal-mask approach associated with Colin Sullivan’s 1981 work. After receiving FDA approval in 1984, Respironics began selling the system commercially in 1985. This helped establish the company in the emerging sleep-apnea treatment market and connected its brand with home-based respiratory therapy. The business expanded its technological scope in the early 1990s. In 1992, it received a patent related to bi-level ventilation. Bi-level systems delivered different pressures during inhalation and exhalation and were subsequently used not only in sleep-disordered breathing but also in other respiratory conditions. Respironics also broadened its market presence through acquisitions: LIFECARE International in 1996 strengthened its ventilator activities; Healthdyne Technologies in 1998 added sleep-apnea expertise and competitive scale; and Novametrix in 2002 contributed monitoring and sensor capabilities. Respironics went public in 1988 under the symbol RESP. Its combination of sleep therapy, ventilation, monitoring, and respiratory accessories made it a significant independent medical-supply company before its acquisition by Philips. On December 21, 2007, Philips announced an agreement to acquire all outstanding Respironics shares for US$66 per share, in a transaction valued at approximately US$5.1 billion. Philips announced completion of its tender offer on March 14, 2008. Respironics subsequently operated as a Philips healthcare business, while its name remained prominent on respiratory and sleep products. The company’s later history was dominated by the 2021 recall of devices containing polyester-based polyurethane sound-abatement foam. The foam had been used in various CPAP, bi-level, and ventilator products. Under certain conditions, including heat and humidity, it could deteriorate and potentially release particles and volatile chemicals into the device’s air path. Philips initiated a global corrective action and replacement program after assessing the issue. The action affected a large installed base and created substantial operational, clinical, legal, and reputational consequences. The recall prompted investigations by the U.S. FDA and other authorities, lawsuits by patients and investors, and public debate about the company’s handling of complaints and risk information. The FDA and Department of Justice later reached a consent-decree arrangement with Philips and Philips Respironics that imposed manufacturing, remediation, and sales restrictions in the United States. Philips also allocated substantial resources to replacement devices, testing, legal settlements, and corrective actions. The company has continued respiratory and sleep-care activities outside the United States, but its product availability and regulatory permissions have remained subject to market-specific requirements and the continuing remediation process.

• 2024

  U.S. consent decree and continuing remediation

  [3]Philips agrees to pay US$479 million to resolve consumer-protection claimsjustice.gov

  A U.S. consent decree imposes compliance, remediation, and sales restrictions connected with the recalled-device program.

• 2021

  Global recall of certain sleep and respiratory devices

  [2]Certain Philips Respironics ventilators, BiPAP machines, and CPAP machines recalledfda.gov

  Philips Respironics recalls or issues safety notifications for devices that may contain degrading sound-abatement foam.

• 2008

  Philips completes the acquisition

  [5]Philips completes tender offer for Respironicsphilips.com

  Philips announces completion of its tender offer for Respironics, bringing the company into Philips’ healthcare operations.

• 2007

  Philips announces acquisition agreement

  [4]Philips to acquire Respironicsphilips.com

  Philips announces an agreement to acquire Respironics for approximately US$5.1 billion, or US$66 per share.

• 2002

  Acquisition of Novametrix

  [1]Philips Respironicsen.wikipedia.org

  Respironics acquires Novametrix, a company associated with medical monitoring and sensor technologies.

• 1998

  Acquisition of Healthdyne Technologies

  [1]Philips Respironicsen.wikipedia.org

  Respironics acquires Healthdyne Technologies, expanding its sleep-apnea business.

• 1996

  Acquisition of LIFECARE International

  [1]Philips Respironicsen.wikipedia.org

  Respironics acquires ventilator manufacturer LIFECARE International.

• 1992

  Bi-level ventilation patent

  [1]Philips Respironicsen.wikipedia.org

  Respironics receives a patent related to bi-level ventilation technology, later associated with treatment of sleep and broader respiratory disorders.

• 1988

  Respironics becomes publicly traded

  [1]Philips Respironicsen.wikipedia.org

  Respironics lists publicly under the ticker symbol RESP.

• 1985

  Commercial CPAP sales begin

  [1]Philips Respironicsen.wikipedia.org

  The company begins commercial sales of its CPAP system, helping establish its sleep-therapy business.

• 1984

  FDA approval for a nasal CPAP system

  [1]Philips Respironicsen.wikipedia.org

  Respironics receives U.S. FDA approval for a nasal CPAP system intended to treat sleep apnea.

• 1976

  Respironics is founded

  [1]Philips Respironicsen.wikipedia.org

  Gerald E. McGinnis establishes Respironics in the Pittsburgh area, initially focusing on anesthesia masks and airway-management products.

A specialist medical-technology brand serving institutional and home-care markets, with an emphasis on sleep-disordered breathing, non-invasive ventilation, respiratory support, and connected care.

• Sleep-apnea therapy systems

  DreamStation

  DreamStation is a family of Philips Respironics positive-airway-pressure devices used primarily for sleep-apnea treatment. Depending on the model and market, the family has included CPAP, auto-adjusting PAP, and related connected-care configurations. The product line became one of the brand’s most visible home-care offerings and was among the families affected by the 2021 foam-related recall and subsequent remediation program.

• Bi-level non-invasive ventilation

  BiPAP systems

  BiPAP is the Philips Respironics family and product designation associated with bi-level positive-airway pressure. These systems provide different inspiratory and expiratory pressure levels and have been used for sleep-disordered breathing and other forms of non-invasive ventilatory support. Models and regulatory status differ by country, and certain devices were included in the 2021 corrective action.

• Continuous positive airway pressure · 1985

  Respironics CPAP systems

  Respironics CPAP systems deliver continuous positive airway pressure through a mask to help keep the upper airway open during sleep. The company’s commercial CPAP activities date to the mid-1980s and formed the basis of its sleep-therapy franchise. Later generations added automated pressure adjustment, data recording, humidification, and connectivity, although particular generations have had different safety and regulatory histories.

• Mechanical ventilation

  Hospital and portable ventilators

  Philips Respironics has supplied ventilators for hospitals, transport, home care, and emergency respiratory support. The ventilator portfolio expanded through internal development and the acquisition of LIFECARE International in 1996. Some ventilator models were included in the 2021 foam-related recall, while subsequent availability has depended on regulatory authorization and remediation requirements.

• Supplemental oxygen equipment

  Oxygen concentrators

  The brand’s oxygen-care offering has included oxygen concentrators for patients requiring supplemental oxygen. These devices separate oxygen from ambient air and can support home-care or ambulatory treatment depending on the model. Availability, indications, and regulatory status are market-specific.

• Patient monitoring

  Infant apnea monitors

  Philips Respironics has offered infant apnea-monitoring products intended to detect pauses in breathing or other indicators requiring clinical attention in infants at risk of respiratory events. Such products form part of the company’s broader respiratory-monitoring and home-care portfolio.

• 2021

  Foam degradation and respiratory-device recall

  Philips Respironics recalled certain CPAP, BiPAP, and ventilator devices after identifying a potential hazard involving degradation of polyester-based polyurethane foam. Regulators, patients, journalists, and litigants subsequently scrutinized the company’s complaint reporting, risk assessment, communications, and remediation. Claims concerning injuries and illnesses have been contested and adjudicated through multiple legal processes; the recall itself and the related regulatory findings are established.

  Source

Read more

• 2021Recall notification and replacement program

  United States · International markets

  Philips Respironics and Philips notified customers and regulators about a recall involving certain sleep and respiratory devices with polyester-based polyurethane sound-abatement foam. The response included device registration, replacement units, repair programs, updated testing, and customer guidance.

  Outcome. The program became a major global remediation effort and remained subject to regulatory oversight, litigation, and market restrictions.

  Source

• 2021

  Recall of devices containing potentially degrading foamOther

  Background

  Philips Respironics identified a potential risk associated with sound-abatement foam used in certain sleep and respiratory devices.

  Action taken

  Philips issued a global recall and safety notification, advised users and clinicians, and began a repair and replacement program.

  Aftermath

  The action led to regulatory investigations, litigation, replacement-device shortages, financial provisions, and restrictions on certain U.S. sales.

  Source

• 2007

  Philips agrees to acquire RespironicsM&A

  Background

  Philips sought to expand its healthcare portfolio in sleep and respiratory care through the acquisition of the publicly traded Respironics business.

  Action taken

  Philips agreed to acquire all Respironics shares for US$66 per share, with an announced transaction value of approximately US$5.1 billion.

  Aftermath

  The tender offer was completed in March 2008, and Respironics became part of Philips’ healthcare activities.

  Announced transaction value. Approximately US$5.1 billion (December 2007 announcement)

  Source

1. 1Philips Respironicsen.wikipedia.org
2. 2Certain Philips Respironics ventilators, BiPAP machines, and CPAP machines recalledfda.gov
3. 3Philips agrees to pay US$479 million to resolve consumer-protection claimsjustice.gov
4. 4Philips to acquire Respironicsphilips.com
5. 5Philips completes tender offer for Respironicsphilips.com